nach oben

Inflammation Research

Erschienen in:

01.11.2009 | Review

The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell

verfasst von: Egle Passante, Neil Frankish

Erschienen in: Inflammation Research | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

The RBL-2H3 cell line is a commonly used histamine-releasing cell line used in inflammation, allergy and immunological research. Quite commonly, it is referred to in research papers as a mast cell line, despite the fact that it is derived from basophils. There is also a lack of consistency, both between different research groups using the same cell line and with both mast cell and basophil physiology. The review follows the development of the RBL-2H3 cell line from its inception and then goes on to assess the nature of the cell line in terms of its characteristics and its response to various stimuli. The relationship of this cell line to the various mast cell subtypes and basophils is discussed and it is concluded that while the RBL-2H3 cell line shares some characteristics with both mast cells and basophils, it is not fully representative of either.

Befus AD, Pearce FL, Gauldie J, Horsewood P, Bienenstock J. Mucosal mast cells. I. Isolation and functional characteristics of rat intestinal mast cells. J Immunol. 1982;128:2475–80.PubMed

Maeyama K, Hohman RJ, Metzger H, Beaven MA. Quantitative relationships between aggregation of IgE receptors, generation of intracellular signals, and histamine secretion in rat basophilic leukemia (2H3) cells. Enhanced responses with heavy water. J Biol Chem. 1986;261:2583–92.PubMed

Seldin DC, Adelman S, Austen KF, Stevens RL, Hein A, Caulfield JP, et al. Homology of the rat basophilic leukemia cell and the rat mucosal mast cell. Proc Natl Acad Sci USA. 1985;82:3871–5.PubMedCrossRef

Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol. 1995;106:377–85.PubMedCrossRef

Gibbs BF, Amon U, Pearce FL. Spontaneous histamine release from mast cells and basophils is controlled by the cellular environment. Inflamm Res. 1997;46(Suppl 1):S25–6.PubMedCrossRef

Boyce JA, Friend D, Matsumoto R, Austen KF, Owen WF. Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med. 1995;182:49–57.PubMedCrossRef

Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 1999;94:2333–42.PubMed

Li L, Li Y, Reddel SW, Cherrian M, Friend DS, Stevens RL, et al. Identification of basophilic cells that express mast cell granule proteases in the peripheral blood of asthma, allergy, and drug-reactive patients. J Immunol. 1998;161:5079–86.PubMed

Denburg JA. Basophil and mast cell lineages in vitro and in vivo. Blood. 1992;79:846–60.PubMed

10.

Church MK, Shute JK, Sampson AP. Mast-Cell derived mediators. In: Middleton’s Allergy: principles and practice. Philadelphia: Elsevier; 2003. p. 186–209.

11.

Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood. 2000;96:4028–38.PubMed

12.

Abraham SN, Arock M. Mast cells and basophils in innate immunity. Semin Immunol. 1998;10:373–81.PubMedCrossRef

13.

Leonard BJ, Eccleston E, Jones D, Lowe J, Turner E. Basophilic leukemia in the rat induced by a-chlorethylamine–ICI 42464. J Pathol. 1971;103:Pxv.PubMed

14.

Eccleston E, Leonard BJ, Lowe JS, Welford HJ. Basophilic leukaemia in the albino rat and a demonstration of the basopoietin. Nat New Biol. 1973;244:73–6.PubMed

15.

Kulczycki A Jr, Isersky C, Metzger H. The interaction of IgE with rat basophilic leukemia cells. I. Evidence for specific binding of IgE. J Exp Med. 1974;139:600–16.PubMedCrossRef

16.

Kulczycki A Jr, Metzger H. The interaction of IgE with rat basophilic leukemia cells. II. Quantitative aspects of the binding reaction. J Exp Med. 1974;140:1676–95.PubMedCrossRef

17.

Siraganian RP, Kulczycki A Jr, Mendoza G, Metzger H. Ionophore A-23187 induced histamine release from rat mast cells and rat basophil leukemia (RBL-1) cells. J Immunol. 1975;115:1599–602.PubMed

18.

Barsumian EL, Isersky C, Petrino MG, Siraganian RP. IgE-induced histamine release from rat basophilic leukemia cell lines: isolation of releasing and nonreleasing clones. Eur J Immunol. 1981;11:317–23.PubMedCrossRef

19.

Taurog JD, Mendoza GR, Hook WA, Siraganian RP, Metzger H. Noncytotoxic IgE-mediated release of histamine and serotonin from murine mastocytoma cells. J Immunol. 1977;119:1757–61.PubMed

20.

Siraganian RP, Metzger H. Evidence that the “mouse mastocytoma” cell line (MCT-1) is of rat origin. J Immunol. 1978;121:2584–5.PubMed

21.

Buell DN, Fowlkes BJ, Metzher H, Isersky C. Cell cycle and morphological changes during growth and differentiation of a rat basophilic leukemia cell line. Cancer Res. 1976;36:3131–7.PubMed

22.

Schroeder JT, Lichtenstein LM, Roche EM, Xiao H, Liu MC. IL-4 production by human basophils found in the lung following segmental allergen challenge. J Allergy Clin Immunol. 2001;107:265–71.PubMedCrossRef

23.

Galli SJ. Mast cells and basophils. Curr Opin Hematol. 2000;7:32–9.PubMedCrossRef

24.

Dvorak AM. Basophil and mast cell degranulation and recovery. In: Harris RJ, editor. Blood cell biochemistry, vol. 4. New York: Plenum Press; 1991.

25.

Dvorak AM. Ultrastructure of mast cell and basophils: Karger; 2005.

26.

Sampson D, Archer GT. Release of histamine from human basophils. Blood. 1967;29:722–36.PubMed

27.

Pearce FL, Befus AD, Gauldie J, Bienenstock J. Mucosal mast cells. II. Effects of anti-allergic compounds on histamine secretion by isolated intestinal mast cells. J Immunol. 1982;128:2481–6.PubMed

28.

Gushchin IS, Zebrev AI. Ketotifen-induced histamine release, inhibition of histamine secretion and modulation of immune response. Agents Actions. 1986;18:92–5.PubMedCrossRef

29.

Fernandez M, Cordoba H, Santos F, Oehling A. In vitro ketotifen protection in bronchial hyperreactivity. J Investig Allergol Clin Immunol. 1991;1:377–82.PubMed

30.

Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev. 2001;179:5–15.PubMedCrossRef

31.

Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, Ozawa H, et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci USA. 2005;102:18105–10.PubMedCrossRef

32.

Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J Immunol. 2001;167:2250–6.PubMed

33.

Bieneman AP, Chichester KL, Chen YH, Schroeder JT. Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion. J Allergy Clin Immunol. 2005;115:295–301.PubMedCrossRef

34.

Komiya A, Nagase H, Okugawa S, Ota Y, Suzukawa M, Kawakami A, et al. Expression and function of toll-like receptors in human basophils. Int Arch Allergy Immunol. 2006;140(Suppl 1):23–7.PubMedCrossRef

35.

Robertson D, Holowka D, Baird B. Cross-linking of immunoglobulin E-receptor complexes induces their interaction with the cytoskeleton of rat basophilic leukemia cells. J Immunol. 1986;136:4565–72.PubMed

36.

Fewtrell C, Metzger H. Larger oligomers of IgE are more effective than dimers in stimulating rat basophilic leukemia cells. J Immunol. 1980;125:701–10.PubMed

37.

Ikawati Z, Wahyuono S, Maeyama K. Screening of several Indonesian medicinal plants for their inhibitory effect on histamine release from RBL-2H3 cells. J Ethnopharmacol. 2001;75:249–56.PubMedCrossRef

38.

Kanda T, Akiyama H, Yanagida A, Tanabe M, Goda Y, Toyoda M, et al. Inhibitory effects of apple polyphenol on induced histamine release from RBL-2H3 cells and rat mast cells. Biosci Biotechnol Biochem. 1998;62:1284–9.PubMedCrossRef

39.

Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006;6:218–30.PubMedCrossRef

40.

Kepley CL, Wilson BS, Oliver JM. Identification of the Fc epsilonRI-activated tyrosine kinases Lyn, Syk, and Zap-70 in human basophils. J Allergy Clin Immunol. 1998;102:304–15.PubMedCrossRef

41.

Tomita U, Inanobe A, Kobayashi I, Takahashi K, Ui M, Katada T. Direct interactions of mastoparan and compound 48/80 with GTP-binding proteins. J Biochem. 1991;109:184–9.PubMed

42.

Tanaka T, Kohno T, Kinoshita S, Mukai H, Itoh H, Ohya M, et al. Alpha helix content of G protein alpha subunit is decreased upon activation by receptor mimetics. J Biol Chem. 1998;273:3247–52.PubMedCrossRef

43.

Mousli M, Bueb JL, Bronner C, Rouot B, Landry Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci. 1990;11:358–62.PubMedCrossRef

44.

Aridor M, Rajmilevich G, Beaven MA, Sagi-Eisenberg R. Activation of exocytosis by the heterotrimeric G protein Gi3. Science. 1993;262:1569–72.PubMedCrossRef

45.

Chahdi A, Fraundorfer PF, Beaven MA. Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. J Pharmacol Exp Ther. 2000;292:122–30.PubMed

46.

Senyshyn J, Baumgartner RA, Beaven MA. Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway. J Immunol. 1998;160:5136–44.PubMed

47.

Buku A, Price JA, Mendlowitz M, Masur S. Mast cell degranulating peptide binds to RBL-2H3 mast cell receptors and inhibits IgE binding. Peptides. 2001;22:1993–8.PubMedCrossRef

48.

Buku A. Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Peptides. 1999;20:415–20.PubMedCrossRef

49.

Passante E, Ehrhardt C, Sheridan H, Frankish N. RBL-2H3 cells are an imprecise model for mast cell mediator release. Inflamm Res. 2009;58(9):611–8.PubMedCrossRef

50.

Dedkova EN, Sigova AA, Zinchenko VP. Mechanism of action of calcium ionophores on intact cells: ionophore-resistant cells. Membr Cell Biol. 2000;13:357–68.PubMed

51.

Ludowyke RI, Scurr LL, McNally CM. Calcium ionophore-induced secretion from mast cells correlates with myosin light chain phosphorylation by protein kinase C. J Immunol. 1996;157:5130–8.PubMed

52.

Johnson HG, Bach MK. Prevention of calcium ionophore-induced release of histamine in rat mast cells by disodium cromoglycate. J Immunol. 1975;114:514–6.PubMed

53.

Passante E, Ehrhardt C, Sheridan H, Frankish N. Toll-like receptors and RBL-2H3 mast cells. Inflamm Res. 2009;58(Suppl 1):11–2.PubMedCrossRef

54.

Hasala H, Giembycz MA, Janka-Junttila M, Moilanen E, Kankaanranta H. Histamine reverses IL-5-afforded human eosinophil survival by inducing apoptosis: pharmacological evidence for a novel mechanism of action of histamine. Pulm Pharmacol Ther. 2008;21:222–33.PubMedCrossRef

55.

Schmidt J, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I. Histamine increases anti-CD3 induced IL-5 production of TH2-type T cells via histamine H2-receptors. Agents Actions. 1994;42:81–5.PubMedCrossRef

56.

Nakatani K, Atsumi M, Arakawa T, Oosawa K, Shimura S, Nakahata N, et al. Inhibitions of histamine release and prostaglandin E2 synthesis by mangosteen, a Thai medicinal plant. Biol Pharm Bull. 2002;25:1137–41.PubMedCrossRef

57.

Kobayashi M, Matsushita H, Yoshida K, Tsukiyama R, Sugimura T, Yamamoto K. In vitro and in vivo anti-allergic activity of soy sauce. Int J Mol Med. 2004;14:879–84.PubMed

58.

Enerback L, Wingren U. Histamine content of peritoneal and tissue mast cells of growing rats. Histochemistry. 1980;66:113–24.PubMedCrossRef

59.

Church MK, Shute JK, Sampson AP. Mass cell-derived mediators. In: Adkinson (ed) Middleton’s allergy: principles and practice: Elsevier, Health Sciences Division; 2003.

60.

Harville BA, Dreyfus LA. Release of serotonin from RBL-2H3 cells by the Escherichia coli peptide toxin STb. Peptides. 1996;17:363–6.PubMedCrossRef

61.

Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature. 1982;297:229–31.PubMedCrossRef

62.

Theoharides TC, Kops SK, Bondy PK, Askenase PW. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell. Biochem Pharmacol. 1985;34:1389–98.PubMedCrossRef

63.

Tamir H, Theoharides TC, Gershon MD, Askenase PW. Serotonin storage pools in basophil leukemia and mast cells: characterization of two types of serotonin binding protein and radioautographic analysis of the intracellular distribution of [3H]serotonin. J Cell Biol. 1982;93:638–47.PubMedCrossRef

64.

Purcell WM, Hanahoe TH. Differential release of histamine and 5-hydroxytryptamine from rat mast cells: the contribution of amine uptake to the apparent pattern of secretion. Agents Actions. 1990;30:38–40.PubMedCrossRef

65.

Williams RM, Shear JB, Zipfel WR, Maiti S, Webb WW. Mucosal mast cell secretion processes imaged using three-photon microscopy of 5-hydroxytryptamine autofluorescence. Biophys J. 1999;76:1835–46.PubMedCrossRef

66.

Seagrave J, Oliver JM. Antigen-dependent transition of IgE to a detergent-insoluble form is associated with reduced IgE receptor-dependent secretion from RBL-2H3 mast cells. J Cell Physiol. 1990;144:128–36.PubMedCrossRef

67.

Dearman RJ, Skinner RA, Deakin N, Shaw D, Kimber I. Evaluation of an in vitro method for the measurement of specific IgE antibody responses: the rat basophilic leukemia (RBL) cell assay. Toxicology. 2005;206:195–205.PubMedCrossRef

68.

Coleman JW. A kinetic analysis of the in vitro sensitization of murine peritoneal mast cells with monoclonal IgE anti-DNP antibody. Immunology. 1988;64:527–31.PubMed

69.

Irman-Florjanc T, Erjavec F. Compound 48/80 and substance P induced release of histamine and serotonin from rat peritoneal mast cells. Agents Actions. 1983;13:138–41.PubMedCrossRef

70.

Gibbs BF. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med. 2005;5:43–9.PubMedCrossRef

71.

Mazurek N, Bashkin P, Petrank A, Pecht I. Basophil variants with impaired cromoglycate binding do not respond to an immunological degranulation stimulus. Nature. 1983;303:528–30.PubMedCrossRef

72.

Mazurek N, Bashkin P, Loyter A, Pecht I. Restoration of Ca2+ influx and degranulation capacity of variant RBL-2H3 cells upon implantation of isolated cromolyn binding protein. Proc Natl Acad Sci USA. 1983;80:6014–8.PubMedCrossRef

73.

Park EK, Choo MK, Kim EJ, Han MJ, Kim DH. Antiallergic activity of ginsenoside Rh2. Biol Pharm Bull. 2003;26:1581–4.PubMedCrossRef

74.

Bissonnette EY, Enciso JA, Befus AD. Inhibition of tumour necrosis factor-alpha (TNF-alpha) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium. Clin Exp Immunol. 1995;102:78–84.PubMedCrossRef

75.

Pearce FL, Befus AD, Bienenstock J. Mucosal mast cells. III. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells. J Allergy Clin Immunol. 1984;73:819–23.PubMedCrossRef

76.

Middleton E Jr, Drzewiecki G, Krishnarao D. Quercetin: an inhibitor of antigen-induced human basophil histamine release. J Immunol. 1981;127:546–50.PubMed

77.

Middleton E Jr, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol. 1992;43:1167–79.PubMedCrossRef

78.

Gushchin IS, Zebrev AI. Characteristics of the effect of ketotifen on the selective and non-selective histamine release from human basophils. Biull Eksp Biol Med. 1984;97:60–3.PubMed

79.

Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol. 2004;4:787–99.PubMedCrossRef

80.

Passante E, Ehrhardt C, Sheridan H, Frankish N. In vitro inhibition of rat basophilic leukaemia mast cell (RBL-2H3) degranulation by novel indane compounds. Inflamm Res. 2008;57(Suppl 1):15–6.CrossRef

81.

Gon Y, Nunomura S, Ra C. Common and distinct signalling cascades in the production of tumour necrosis factor-alpha and interleukin-13 induced by lipopolysaccharide in RBL-2H3 cells. Clin Exp Allergy. 2005;35:635–42.PubMedCrossRef

82.

Froese A, Helm RM, Conrad DH, Isersky C, Ishizaka T, Kulczycki A Jr. Comparison of the receptors for IgE of various rat basophilic leukaemia cell lines. I. Receptors isolated by IgE-sepharose and IgE and anti-IgE. Immunology. 1982;46:107–16.PubMed

83.

Froese A, Helm RM, Conrad DH, Isersky C, Ishizaka T. Comparison of the receptors for IgE of various rat basophilic leukaemia cell lines. II. Studies with different anti-receptor antisera. Immunology. 1982;46:117–23.PubMed

84.

Magro AM, Alexander A. Histamine release: in vitro studies of the inhibitory region of the dose-response curve. J Immunol. 1974;112:1762–5.PubMed

85.

Ortega E, Schweitzer-Stenner R, Pecht I. Possible orientational constraints determine secretory signals induced by aggregation of IgE receptors on mast cells. Embo J. 1988;7:4101–9.PubMed

86.

Nakano T, Sonoda T, Hayashi C, Yamatodani A, Kanayama Y, Yamamura T, et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med. 1985;162:1025–43.PubMedCrossRef

87.

Kanakura Y, Thompson H, Nakano T, Yamamura T, Asai H, Kitamura Y, et al. Multiple bidirectional alterations of phenotype and changes in proliferative potential during the in vitro and in vivo passage of clonal mast cell populations derived from mouse peritoneal mast cells. Blood. 1988;72:877–85.PubMed

88.

Taketomi Y, Sugiki T, Saito T, Ishii S, Hisada M, Suzuki-Nishimura T, et al. Identification of NDRG1 as an early inducible gene during in vitro maturation of cultured mast cells. Biochem Biophys Res Commun. 2003;306:339–46.PubMedCrossRef

89.

Swieter M, Midura RJ, Nishikata H, Oliver C, Berenstein EH, Mergenhagen SE, et al. Mouse 3T3 fibroblasts induce rat basophilic leukemia (RBL-2H3) cells to acquire responsiveness to compound 48/80. J Immunol. 1993;150:617–24.PubMed

Titel: The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell
verfasst von: Egle Passante
Neil Frankish
Publikationsdatum: 01.11.2009
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 11/2009
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-009-0074-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2009

Inhibition of CD203c membrane up-regulation in human basophils by high dilutions of histamine: a controlled replication study

Intranasal challenge with increasing ovalbumin doses differently affects airway hyperresponsiveness and inflammatory cell accumulation in mouse model of asthma

Lipoteichoic acid improves the capability of mast cells in the host defense system against bacteria

Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice

Simvastatin does not prevent acute cardiac allograft rejection in CD28-deficient mice

Potential role of the TLR4/IRAK-4 signaling pathway in the pathophysiology of acute pancreatitis in mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin